阿立哌唑与利培酮治疗首发精神分裂症

Comparison of aripiprazole and risperidone in the treatment of first-episode schizophrenia

目的:评价阿立哌唑与利培酮治疗首发精神分裂症的疗效和安全性。方法:50例患者为阿立哌唑治疗组;50例患者为利培酮治疗组。采用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)分别评定疗效和不良反应。结果:阿立哌唑组与利培酮组的总体疗效相当,阿立哌唑组PANSS-阴性症状在第2周开始,减分项目优于利培酮组;TESS量表评估显示利培酮引起锥体外系反应、体重增加、性功能异常、胆碱能系统等不良反应发生率较阿立哌唑高。结论:阿立哌唑与利培酮治疗首发精神分裂症疗效相当,但阿立哌唑不良反应少,依从性好,比较适合于阴性症状为主的首发精神分裂症患者。

Objective： To assess the efficacy and safety of aripiprazole and risperidone in the treatment of first-episode schizophrenia. Methods： 50 patients were given aripiprazole, while other 50 cases were given risperidon. Positive and negative syndrome scale （PANSS） and adverse reactions table （TESS） was respectively applied for the assessment of efficacy and adverse reactions. Results： Aripiprazole had the same efficacy as risperidone. However, for aripiprazole group, PANSS-nega- tive syndrome occurred at the beginning of the 2nd week with better project reduction than the ris- peridone group. And there were more adverse reactions caused by risperidone, including extrapyra-midal reactions, weight gain, sexual dysfunction and cholinergic systems. Conclusion： Aripiprazole should be applicable to treat first-episode schizophrenia for the rare adverse reactions, good treat-ment compliance.